Key Insights

Highlights

Success Rate

94% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Low Risk

Score: 17/100

Termination Rate

4.8%

1 terminated out of 21 trials

Success Rate

93.8%

+7.2% vs benchmark

Late-Stage Pipeline

57%

12 trials in Phase 3/4

Results Transparency

60%

9 of 15 completed with results

Key Signals

9 with results94% success

Data Visualizations

Phase Distribution

19Total
Not Applicable (1)
P 1 (3)
P 2 (3)
P 3 (9)
P 4 (3)

Trial Status

Completed15
Unknown3
Withdrawn2
Terminated1

Trial Success Rate

93.8%

Benchmark: 86.5%

Based on 15 completed trials

Clinical Trials (21)

Showing 20 of 20 trials
NCT05101928Phase 4Withdrawn

Ozurdex Monotherapy Trial

NCT02725177Not ApplicableCompleted

Ocular Sarcoidosis Open Label Trial of ACTHAR Gel

NCT01280669Phase 2Withdrawn

Intravitreal Sirolimus as Therapeutic Approach to Uveitis

NCT06085079Phase 4Unknown

Ixekizumab for the Management of Refractory Non-Infectious Uveitis: A Proof-of-Concept Study

NCT03656692Phase 4Terminated

Safety and Effectiveness of Acthar Gel for Inflammation of the Eye's Uvea (Middle Layer)

NCT03097315Phase 3Completed

Suprachoroidal Injection of CLS-TA in Patients With Non-infectious Uveitis

NCT02952001Completed

MAGNOLIA: Extension Study of Patients With Non-infectious Uveitis Who Participated in CLS1001-301

NCT02595398Phase 3Completed

Suprachoroidal Injection of CLS-TA in Subjects With Macular Edema Associated With Non-infectious Uveitis

NCT01789320Phase 1Completed

Safety Study of Suprachoroidal Triamcinolone Acetonide Via Microneedle to Treat Uveitis

NCT02255032Phase 2Completed

Suprachoroidal Injection of Triamcinolone Acetonide in Subjects With Macular Edema Following Non-Infectious Uveitis

NCT00615693Phase 2Completed

Safety, Tolerability, and Efficacy of AEB071 in the Treatment of Uveitis

NCT02746991Phase 3Completed

Safety and Efficacy Study of a FAI Insert in Subjects With Chronic Non-infectious Posterior Uveitis

NCT00908466Phase 1Completed

Sirolimus as Therapeutic Approach to Uveitis

NCT00167583Phase 3Completed

Interferon-alpha2a Versus Cyclosporin A for Severe Ocular Behcet's Disease (INCYTOB)

NCT01717170Phase 1Unknown

Study of the Safety, Tolerability, and Bioactivity of Tocilizumab On Patients With Non-infectious UVEITIS: The STOP-UVEITIS Study

NCT00404612Phase 3Completed

A Study of LX211 in Active Sight Threatening, Non-infectious Intermediate-, Anterior and Intermediate-, Posterior-, or Pan-Uveitis

NCT00404885Phase 3Completed

A Multi-center Study to Assess the Efficacy and Safety of LX211 in Active Non-infectious Anterior Uveitis

NCT00404742Phase 3Completed

A Study of LX211 in Clinically Quiescent Non-infectious Intermediate, Anterior and Intermediate, Posterior or Pan-Uveitis

NCT00407316Unknown

Quality of Life and Visual Function in Uveitis Patients

NCT00407056Phase 3Completed

Study of Difluprednate Ophthalmic Emulsion in the Treatment of Severe Uveitis

Scroll to load more

Research Network

Activity Timeline